• Home
  • Live CME Meetings
  • Online CME
  • CME Publications
  • CME Tracker/Planner

Pri-Med Updates Washington, DC 2008

Location: Washington, DC
Date: June 03-04, 2008
Session
Summary

Meeting Overview

Venue:
Renaissance Washington, DC Hotel
Primary Audience:
Primary Care
Credits:
15 AMA Category 1, AAFP, 15 AANP

A Fresh Look at the Real-World Challenges of Primary Care

Pri-Med Updates is designed to reflect the practitioner's patient appointment schedule. The curriculum is composed of 12 different symposia, each focused on a specific clinical condition and each presented by nationally-recognized speakers. Sessions include didactic presentations as well as interactive, case-based learning opportunities. The goal is to connect current research and leading opinion to insights you can put into practice at once, while enabling you to earn a maximum of 15 AMA PRA Category 1 Credit(s)TM at no cost to you.

This activity is intended for primary care providers currently engaged in patient care.

Goals and Objectives

Attend this continuing education activity and you will be able to:

  • Earn up to 15 AMA PRA Category 1 Credit(s)TM.
  • Network with colleagues who live and practice in your area.
  • Take advantage of a complimentary world-class continuing medical education.
  • Interact with expert faculty during dedicated Q&A throughout the program.
  • Test your knowledge and receive immediate feedback on patient care scenarios using an Audience Response System.

 

Marketing Partners

Pri-Med partners with local healthcare associations, managed care organizations, and publications in order to ensure that all practicing clinicians have the opportunity to attend. Pri-Med would like to thank the following partners for this program to date: Aetna, American Academy of Nurse Practitioners, American Society of Hypertension, Inc., CIGNA HealthCare, and Medical Society of the District of Columbia.

Educational Grants

To date, the following organizations have provided educational grants in support of this Pri-Med activity: Abbott, Allergan, Inc, Boehringer Ingelheim Pharmaceuticals, Inc., Forest Pharmaceuticals, Inc., GlaxoSmithKline, Merck & Co., Inc., Merck/Schering-Plough Pharmaceuticals, Novartis Pharmaceuticals Corporation, Shire Pharmaceuticals Inc., and M|C Communications, LLC.

Session Summary

Following is a recap of the core educational elements from the conference sessions, to help you take what you learned and apply it to your interactions with patients.

View Schedule for:
Tuesday, June 03, 2008
7:45 AM-9:00 AM
Management of Morbid Obesity: Tools for Confronting the Epidemic

Description:

1. Understand the critical role of the primary care practitioner in developing long-term success strategies for managing obesity. 2. Learn the latest options for treating obesity including lifestyle modification, bariatric surgery, and the newest pharmacologic agents.
Kelly Anne Spratt, DO, Clinical Associate Professor of Medicine, Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, PA
9:15 AM-10:30 AM
Using Combination Therapy to Improve Atherogenic Lipid Abnormalities and Reduce Residual Cardiovascular Risk

Description:

1. Discuss how specific populations at high risk of coronary heart disease--including those with diabetes and metabolic syndrome--can benefit from aggressive lipid management. 2. Describe emerging evidence that supports the use of combination pharmacotherapy in the cardioprotective management of high-risk patients.
James A. Underberg, MD, Clinical Asst. Professor of Medicine, New York University School of Medicine, New York, NY
Peter Alagona, Jr, MD, Assoc. Professor of Medicine, Milton S. Hershey Medical Center, Hershey, PA

Related CME

Featured Activities FormatCreditsExpiresStatus
Optimally Reducing Residual Cardiovascular Disease Risk in a Patient With Atherogenic DyslipidemiaPatient Case Study2 AMA1
2 AANP
04/30/2009
10:45 AM-12:00 PM
Adult ADHD: When Comorbidities Are the Tip of the Iceberg

Description:

1: Learn when it's appropriate to switch, stop, or resume medication in order to maximize health-related quality of life in patients with ADHD. 2: Evaluate the implications of drug abuse, comorbidities, and cardiovascular risk as important considerations in ADHD treatment.
Peter J. Knoblich, MD, Private Practice, Roseville, CA
Thomas Schwartz, MD , Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse,

Related CME

Featured Activities FormatCreditsExpiresStatus
Adult ADHD: When Comorbidities Are the Tip of the IcebergSlide Lecture Series2 AMA1
2 AANP
03/23/2009
12:30 PM-1:45 PM
Vasodilatory ß-Blockade: Clinical Implications and Pleiotropic Effects
Henry A. Punzi, MD, Medical Director, Punzi Medical Center , Trinity Hypertension Research Institute, Carrollton, TX, Clinical Professor, Allied Health Institute, Texas Women's University, Dallas, TX
Elijah Saunders, MD, FACC, FACP, Professor of Medicine, Head, Section of Hypertension in the division of Cardiology, University of Maryland School of Medicine, Baltimore, MD
2:00 PM-3:15 PM
What Every Practitioner Should Know About Incretin Hormones:"Evolving Treatment Strategies for Type 2 Diabetes"

Description:

1. Cite the stepwise treatment algorithm recommended by the American Diabetes Association. 2. Identify patients for whom it is appropriate to deviate from this algorithm.
John B. Buse, MD, PhD, CDE, FACE, Director, Diabetes Care Center, University of North Carolina , Chapel Hill, NC
Bernard Zinman, MD, Director, Leadership Centre for Diabetes, University of Toronto, Toronto, ON

Related CME

Featured Activities FormatCreditsExpiresStatus
What Every Practitioner Should Know About Incretin Hormones: Evolving Treatment Strategies for Type 2 DiabetesPatient Case Study2 AMA1
2 AANP
04/24/2009
3:15 PM-4:30 PM
The Many Faces of Fibromyalgia: Improving Diagnosis and Treatment of a Complex Disease

Description:

1. Using case-based examples, evaluate both mental and physical criteria that lead to a diagnosis of fibromyalgia. 2. Identify 2 common comorbidities associated with fibromyalgia and apply this information to your diagnostic strategy in your practice.
Martin J. Bergman, MD, Chief, Division of Rheumatology, Taylor Hospital, Ridley Park, PA
Daniel Clauw, MD, Professor of Internal Medicine and Rheumatology, University of Michigan, Ann Arbor, MI
Wednesday, June 04, 2008
7:45 AM-9:00 AM
The Moving LDL Target: Getting Your Patients to Goal!

Description:

1. Compare and contrast the current lifestyle and pharmacologic treatment options available for lipid management. 2. Define the patients at increased risk for cardiovascular events and identify at least 2 lipid lowering strategies that will help these patients reach goal
Robert M. Schainfeld, DO, Lecturer on Medicine, Harvard Medical School, Boston, MA
Muredach P. Reilly, MB, Cardiovascular Medicine Division, University of Pennsylvania Medical Center, Philadelphia, PA
9:15 AM-10:30 AM
Overactive Bladder: Improving Outcomes, Preserving Quality of Life

Description:

1. Differentiate available agents for the treatment of OAB based on pharmacologic and pharmacokinetic characteristics and the impact of these characteristics on efficacy, safety, and tolerability. 2. Implement a treatment plan for OAB that balances efficacy, safety, and tolerability to improve treatment persistence and quality of life.
Diane K. Newman, RNC, MSN, CRNP, FAA, Co-Director, Pennsylvania Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania, Philadelphia, PA
Pamela I. Ellsworth, MD, Associate Professor of Urology, Brown University, Providence, RI

Related CME

Featured Activities FormatCreditsExpiresStatus
A 75-Year-Old Woman with Nocturia and Forgetfulness Patient Case Study2 AMA1
2 AANP
03/14/2009
10:45 AM-12:00 PM
RLS Live! Overcoming Barriers to Patient Care

Description:

1. Identify effective communication techniques that establish a productive partnership with patients, expediting diagnosis and enhancing patient outcomes. 2. Recognize the incidence of restless legs syndrome (RLS) and list several treatment options for managing intermittent, daily, and refractory symptoms.
Michael J. Thorpy, MD, (Read Bio) Professor of Neurology, Albert Einstein College of Medicine, Bronx, NY
Mathew M. Clark, MD, MA, Associate Director, Family Medicine Residency Program, Abington Memorial Hospital, Abington, PA, Clinical Professor of Family and Community Medicine, Temple University School of Medicine, Philadelphia, PA
12:30 PM-1:45 PM
Benefit to Risk Ratios for Treatment of Type 2 Diabetes

Description:

1. Cite the stepwise treatment algorithm recommended by the American Diabetes Association. 2. Describe the risk-benefit analysis of using thiazolidinediones in patients with type 2 diabetes.
Bruce Trippe, MD, FACE, Director, Growth hormone deficiency syndrome, thryoid cancer research, Clinical Researcher in Diabetes, Metabolic/Weight Loss,, Diabetes Complication and Prevention Treatment Clinics, Montgomery, AL
2:00 PM-3:15 PM
Achieving Blood Pressure Goals With Multidrug Therapy--Where Do Renin Inhibitors Fit In?

Description:

Assess evidence-based treatments for hypertension, including the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors.
Henry R. Black, MD, Clinical Professor of Internal Medicine, Center for the Prevention of Cardiovascular Disease, Director of Hypertension Research, NYU School of Medicine, New York, NY
Debbie L. Cohen, MD, Assistant Professor of Medicine, Director of Clinical Hypertension Programs, Renal Electrolyte and Hypertension Division, University of Pennsylvania Health System, Philadelphia, PA

Related CME

Featured Activities FormatCreditsExpiresStatus
Side Effects During Antihypertensive Therapy in a 55-Year-Old ManPatient Case Study2 AMA1
2 AANP
03/13/2009
3:15 PM-4:30 PM
Key Concepts for Unlocking the Door to Detection and Management of Genital Herpes

Description:

Understand the relationship between asymptomatic shedding of herpes simplex virus type 2 (HSV-2) and the potential for transmission. Counsel HSV-2 infected patients on effective methods that can reduce HSV-2 outbreaks and the risk of HSV-2 transmission.
Edward Hook, MD, Porfessor of Medicine, University of Alabama at Birmingham, Birmingham, AL

Accreditation

CreditsTypeAccreditation StatementDesignation Statement
15AMA Category 1Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Pri-Med Institute designates this educational activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PendingAAFPApplication for CME credit has been filed with American Academy of Family Physicians. Determination of credit is pending.
15AANPPri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308.This program has been approved for 15 contact hour of continuing education , which includes 7.500 hours of pharmacology.

Academic Partner

Pri-Med Institute gratefully acknowledges the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute for serving as academic partners in the review of educational content.

Statement of Independence

This educational program is conceived and credited in accordance with ACCME’s Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute’s Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.

Travel

Meeting Location

Renaissance Washington, DC Hotel
999 9th St, NW
Washington, DC 20001
(202)898-9000

Hotel Accommodations

A limited number of rooms have been reserved at the Renaissance Washington, DC Hotel. Please call (202)898-9000 by 05/12/2008 and identify yourself as a Pri-Med Updates attendee to receive the discounted rate of $289.

Additional Opportunities

The Science & Management of Menopause: Perspectives on Hormone Therapy

Tuesday, June 3, 2008 at 5:00 pm

This program is an opportunity to learn about menopause, associated symptoms, and hormone therapy. It was designed to educate on the following objectives:

  • To discuss the physiology, prevalence, and severity of menopausal symptoms,
    including vasomotor symptoms and vulvovaginal symptoms, as well as postmenopausal osteoporosis.
  • To review the evidence supporting the efficacy and safety of hormone therapy in the appropriate treatment of menopausal symptoms in postmenopausal women.
  • To explore techniques for counseling patients on menopause, symptoms, treatment goals, and risks associated with therapy.

This program is not planned nor is the content reviewed by the Pri-Med Institute.
This program is not offered for CME Credit.